Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies


Sygnature’s experienced medicinal chemistry and bioscience team have a wealth of expertise and a strong track record of delivery in anti-bacterial, anti-fungal and anti-viral drug discovery. Building on this expertise, Sygnature has established an anti-viral screening platform, to facilitate the support of integrated anti-infective discovery programs.

Established anti-viral assays include:

  • Cytopathic effect (CPE) screen: test compounds are evaluated for their ability to inhibit virus-induced CPE. Cells are pre-treated with test compounds and infected with the virus of interest. After a virus-specific incubation period, cells are assessed for their viability relative to an untreated virus-only control.
  • Neutralization assays: the virus is incubated with test compounds before suitable cells are infected.
    • Plaque-reduction neutralization.
    • Microneutralization (measurement of cell survival similar to CPE assays).
  • Progeny-reduction assays: Cells are incubated with test compounds and infected with the virus of choice. After a virus-specific incubation time the supernatants are harvested and the virus titre is determined using a method suitable for the selected virus (50% Tissue culture Infective Dose (TCID50), plaque assays, immunoplaques).
  • ELISAs: measurement of cytokine secretion in response to viral infection and as a measurement of any inflammatory or anti-inflammatory activity of test compounds.
  • RT-qPCR: the detection of viruses in cell supernatant as a diagnostic or as a measure of viral replication.
  • Mechanism of action studies: investigation into the effect of viral replication, viral fusion and infectivity as a means of determining the inhibitory mechanism of test compounds.
  • Customizable virus production: use of mammalian cell culture for virus growth and harvesting, with titration performed by plaque assay.
  • Microscopy-based anti-viral and anti-bacterial high content screening: the measurement of changes in cellular phenotype following viral or anti-viral infections, as well as in response to the use of test compounds.

To complement the range of anti-viral assay available in-house, we also perform host cell cytotoxicity analysis of the compounds to ensure your compound’s efficacy data is meaningful with respect to therapeutic window.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

Oncology and Immuno-oncology

We have successfully delivered more than 16 pre-clinical oncology projects, utilising our Integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. From initial screening and profiling through to clinically relevant Biomarkers, our DMPK and bioscience group can provide full support for your discovery projects.



Diabetes is a metabolic disorder that is an increasingly prevalent disease worldwide. We have established assays to support the investigation of diabetic therapies including relevant functional assays. We also have access to tissue and blood from in vivo diabetic models through strategic collaborations.


Orphan Disease

Sygnature’s team of scientists have a strong track record of adding value to client projects in the field of rare and orphan diseases.  Sygnature’s advanced intellectual input and established relationships with providers of diseased tissue allows rapid progression of projects in this challenging therapeutic area.



Sygnature have a history of enabling discovery success in the field of anti-infectives. Our Medicinal Chemistry and Computational Chemistry teams have worked in close collaboration with many clients to design potent and efficacious compounds, resulting in the delivery of two preclinical candidates. Our Bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells.



Our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (CNS). Our experience is both broad, reaching across a number of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in CNS drug research.



We have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. Our collaborative approach to drug discovery and our established network of KOLs in the field have been invaluable to the progression of our clients’ projects


Inflammation and Immunology

Our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising Peripheral Blood Mononuclear Cells (PBMCs), T lymphocytes (e.g. CD4+/CD8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints.